The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction
Abstract
BACKGROUND: The combination of glycoprotein IIb/IIIa inhibitors and heparin has not been compared with bivalirudin in studies specifically involving patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI). We compared the two treatments in this patient population. METHODS: Immediately before PCI, we randomly assigned, in a double-blind manner, 1721 patients with acute non-ST-segment elevation myocardial infarction to receive abciximab plus unfractionated heparin (861 patients) or bivalirudin (860 patients). The study tested the hypothesis that abciximab and heparin would be superior to bivalirudin with respect to the primary composite end point of death, large recurrent myocardial infarction, urgent target-vessel revascularization, or major bleeding within 30 days. Secondary end points included the composite of death, any recurrent myocardial infarction, or urgent target-vessel revascularization (efficacy end point) and major bleeding (safety end point) within 30 days. RESULTS: The primary end point occurred in 10.9% of the patients in the abciximab group (94 patients) and in 11.0% in the bivalirudin group (95 patients) (relative risk with abciximab, 0.99; 95% confidence interval [CI], 0.74 to 1.32; P=0.94). Death, any recurrent myocardial infarction, or urgent target-vessel revascularization occurred in 12.8% of the patients in the abciximab group (110 patients) and in 13.4% in the bivalirudin group (115 patients) (relative risk, 0.96; 95% CI, 0.74 to 1.25; P=0.76). Major bleeding occurred in 4.6% of the patients in the abciximab group (40 patients) as compared with 2.6% in the bivalirudin group (22 patients) (relative risk, 1.84; 95% CI, 1.10 to 3.07; P=0.02). CONCLUSIONS: Abciximab and unfractionated heparin, as compared with bivalirudin, failed to reduce the rate of the primary end point and increased the risk of bleeding among patients with non-ST-segment elevation myocardial infarction who were undergoing PCI. (Funded by Nycomed Pharma and others; ISAR-REACT 4 ClinicalTrials.gov number, NCT00373451.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Bivalirudin during Primary PCI in Acute Myocardial Infarction
Stone, G. W., Witzenbichler, B., Guagliumi, G., Peruga, J. Z., Brodie, B. R., Dudek, D., Kornowski, R., Hartmann, F., Gersh, B. J., Pocock, S. J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708191 · Cited by 1,867
Authors/Task Force Members, Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm161 · Cited by 1,849
Bivalirudin for Patients with Acute Coronary Syndromes
Stone, G. W., McLaurin, B. T., Cox, D. A., Bertrand, M. E., Lincoff, A. M., Moses, J. W., White, H. D., Pocock, S. J., Ware, J. H., Feit, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062437 · Cited by 1,459
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
Lincoff, A. M., Bittl, J. A., Harrington, R. A., Feit, F., Kleiman, N. S., Jackman, J. D., Sarembock, I. J., Cohen, D. J., Spriggs, D., Ebrahimi, R., et al. (2003) · JAMA · doi:10.1001/jama.289.7.853 · Cited by 1,162
Kastrati, A. (2006) · JAMA · doi:10.1001/jama.295.13.joc60034 · Cited by 751
Self-citationAngioscopic Evaluation of Coronary-Artery Thrombi in Acute Coronary Syndromes
Mizuno, K., Satomura, K., Miyamoto, A., Arakawa, K., Shibuya, T., Arai, T., Kurita, A., Nakamura, H., & Ambrose, J. A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260502 · Cited by 591
Kastrati, A., Mehilli, J., Schühlen, H., Dirschinger, J., Dotzer, F., ten Berg, J. M., Neumann, F.-J., Bollwein, H., Volmer, C., Gawaz, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031859 · Cited by 567
Self-citation
Cited by
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citation2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
Self-citation2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Self-citationCollet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Metadata
- Authors
- Kastrati, A., Neumann, F.-J., Schulz, S., Massberg, S., Byrne, R. A., Ferenc, M., Laugwitz, K.-L., Pache, J., Ott, I., Hausleiter, J., Seyfarth, M., Gick, M., Antoniucci, D., Schömig, A., Berger, P. B., & Mehilli, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-11-24
- Volume
- 365
- Issue
- 21
- Pages
- 1980-1989
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2073159589
- Cited by
- 314
- References
- 19
- FWCI
- 24.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction. https://app.cochat.ai/papers/10.1056/nejmoa1109596
- The paper
- Kastrati, A., Neumann, F.-J., Schulz, S., Massberg, S., Byrne, R. A., Ferenc, M., Laugwitz, K.-L., Pache, J., Ott, I., Hausleiter, J., Seyfarth, M., Gick, M., Antoniucci, D., Schömig, A., Berger, P. B., & Mehilli, J. (2011). Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1109596
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.